Tamoxifen and Risk of Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers.
- Phillips, Kelly-Anne
- Milne, Roger L
- Rookus, Matti A
- Daly, Mary B
- Antoniou, Antonis C
- Peock, Susan
- Frost, Debra
- Easton, Douglas F
- Ellis, Steve
- Friedlander, Michael L
- Buys, Saundra S
- Andrieu, Nadine
- Noguès, Catherine
- Stoppa-Lyonnet, Dominique
- Bonadona, Valérie
- Pujol, Pascal
- McLachlan, Sue Anne
- John, Esther M
- Hooning, Maartje J
- Seynaeve, Caroline
- Tollenaar, Rob A E M
- Goldgar, David E
- Terry, Mary Beth
- Caldes, Trinidad
- Weideman, Prue C
- Andrulis, Irene L
- Singer, Christian F
- Birch, Kate
- Simard, Jacques
- Southey, Melissa C
- Olsson, Håkan
- Jakubowska, Anna
- Olah, Edith
- Gerdes, Anne-Marie
- Foretova, Lenka
- Hopper, John L
Publication date
January 2013
DOI Publisher
American Society of Clinical Oncology (ASCO)Abstract
To determine whether adjuvant tamoxifen treatment for breast cancer (BC) is associated with reduced contralateral breast cancer (CBC) risk for BRCA1 and/or BRCA2 mutation carriers
Add to ORKG